Kura Oncology, Inc. · NASDAQ:KURA

Kura Oncology — Technical Presentation (November 2020)

12 slides from Kura Oncology's technical presentation, November 2020

  1. Slide 1: Preliminary Data Report on a Phase 1/2A First in Human Study of KO-539 in R/R AML

    Preliminary Data Report on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia Eunice S. Wang1, Jessica Altman2, Kristen Pettit3, Stephane DeBotton4, Roland Walter5, Pierre Fenaux6, Francis Burrows7, Blake Tomkins

  2. Slide 2: KO-539 is a Potent and Selective Oral Inhibitor of the Menin-KMT2A (MLL) Complex

    KO-539 is a Potent and Selective Oral Inhibitor of the Menin-KMT2A (MLL) Complex NPM1 mutant Mutant Mutant IDH1/2 NPM1 MEIS1 HOXA9 FLT3 FLT3 KMT2A MEIS1 Leukemia Differentiation Menin HOXA9 HOXA9, MEIS1 promoters MEIS1 KMT2A (MLL)-rearranged HOXA9 KMT2A-r (MLL-r) Menin DOT1L

  3. Slide 3: Key KO-539 Preclinical Toxicology and Pharmacokinetics Findings

    Key KO-539 Preclinical Toxicology and Pharmacokinetics Findings • Toxicology/Safety Pharmacology – No evidence of QTc prolongation in dogs – Low torsadogenic risk based on key cardiac ion channels interactions • Pharmacokinetics – Primarily metabolized by CYP3A4 generating biologically two active me

  4. Slide 4: KOMET-001 is a Phase 1/2A First-in-Human Study of KO-539 in Patients with Relapsed/Refractory AML

    KOMET-001 is a Phase 1/2A First-in-Human Study of KO-539 in Patients with Relapsed/Refractory AML MTD, maximum tolerated dose NCT04067336 mTPI, modified toxicity probability interval

  5. Slide 5: Patient Demographics and Baseline Characteristics

    Patient Demographics and Baseline Characteristics KOMET-001 Patients N=12 Median Age, y (min, max) 67 (33, 80) Gender, n (%) Male 8 (66.7%) Female 4 (33.3%) Race, n (%) White 8 (66.7%) Number of prior lines of therapies, median (range) 3 (2-7) Number of patients with prior transplant 1 Data as of 02

  6. Slide 6: Patient Status Summary

    Patient Status Summary Disposition & Discontinuation KOMET-001 Patients N=12 Patients in Treatment 6 Patients in Follow-Up 1 Patients off Study 5 Reason for Study Treatment Reason for Study N=6 N=5 Discontinuation Discontinuation Symptomatic Deterioration 1 Death 2 Disease Progression as 4 Physician

  7. Slide 7: KO-539 Demonstrates Encouraging Early Clinical Activity

    KO-539 Demonstrates Encouraging Early Clinical Activity *Expanded to characterize PK Data as of 02 November 2020

  8. Slide 8: Continuous Daily Dosing of KO-539 Has Been Well-Tolerated with a Manageable Safety Profile

    Continuous Daily Dosing of KO-539 Has Been Well-Tolerated with a Manageable Safety Profile ➢ No dose discontinuations due to treatment-related AEs ➢ No evidence of QT prolongation or other clinically significant ECG changes Treatment-related AEs (N=12) Grade ≥ 3 Grade 1,2 (all) (≥ 10%) Pancreatitis

  9. Slide 9: Dose-related Increase in Exposure and Wide Inter-Patient Variability in Patients

    Dose-related Increase in Exposure and Wide Inter-Patient Variability in Patients Plasma KO-539 Exposure Cycle 1, Day 1 3000 AUC0-24 hr (ng.hr/mL) 2000 1000 600 500 400 300 200 100 0 50 100 200 400 Dose (mg) Median n=11; exposure (i.e., AUC0-24 hr) not evaluable in one patient

  10. Slide 10: KO-539 Pharmacokinetics Do Not Appear to be Affected by Co-administration of a CYP3A4 Inhibitor

    KO-539 Pharmacokinetics in Patients Do Not Appear to be Affected by Co-administration of an CYP3A4 Inhibitor Dose Adjusted KO-539 AUC0-24 hr Dose Adjusted KO-539 Cmax Cycle 1, Day 1 Cycle 1, Day 1 12 1.0 AUC0-24 hr/Dose (ng.hr/mL)/mg Cmax/Dose (ng/mL)/mg 10 0.8 8 0.6 6 0.4 4 0.2 2 0 0.0 None Moderat

  11. Slide 11: Conclusions

    Conclusions • KO-539 is a potent and selective inhibitor of the Menin-KMT2A (MLL) complex • KO-539 demonstrates early encouraging clinical activity in different genomic subgroups • KO-539 has been well tolerated and with a manageable safety profile to date • Plasma KO-539 exposure increases with dos

  12. Slide 12: Acknowledgements

    Acknowledgements • The patients, their families and caregivers • The study investigators and their study teams • The study is sponsored by Kura Oncology, Inc.

Kura Oncology — Technical Presentation (November 2020) on 6ix